Codexis, Inc. (CDXS)
Automate Your Wheel Strategy on CDXS
With Tiblio's Option Bot, you can configure your own wheel strategy including CDXS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CDXS
- Rev/Share 0.6045
- Book/Share -0.8206
- PB 3.7528
- Debt/Equity 1.1988
- CurrentRatio 3.7227
- ROIC 10.545
- MktCap 187229248.0
- FreeCF/Share -0.7262
- PFCF -3.1283
- PE -2.5013
- Debt/Assets 5.1132
- DivYield 0
- ROE -1.1847
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CDXS | The Benchmark Company | Buy | Hold | -- | -- | Aug. 19, 2024 |
News
Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases
Read More
Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Codexis, Inc. (NASDAQ:CDXS ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive Officer Kevin Norrett - Chief Operating Officer Georgia Erbez - Chief Financial Officer Conference Call Participants Richard Miller - Cantor Fitzgerald, L.P. Matthew Stanton - Jefferies Group LLC Allison Bratzel - Piper Sandler Companies Dan Arias - Stifel Financial Corp. Jacob Johnson - Stephens Inc. Matthew Hewitt - Craig-Hallum Capital Group LLC Brendan Smith - TD Cowen Operator Welcome to the Codexis Fourth Quarter and Full Year 2024 Earnings …
Read More
Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.02 per share a year ago.
Read More
Codexis Announces New Employment Inducement Grants
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 39,000 shares of Codexis common stock and (ii) 27,500 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan.
Read More
About Codexis, Inc. (CDXS)
- IPO Date 2010-04-22
- Website https://www.codexis.com
- Industry Biotechnology
- CEO Dr. Stephen George Dilly MBBS, Ph.D.
- Employees 188